There is a newer version
of
this Section
2021 Maryland Statutes
Health - General
Title 21 - Food, Drugs, and Cosmetics
Subtitle 2C - Prescription Drug Affordability Board
Section 21-2C-16 - Board and Stakeholder Council Report and Recommendation Concerning Upper Payment Limits
Universal Citation: MD. Health - General Code Ann. § 21-2C-16 (2021)
On or before December 1, 2023, the Board, in consultation with the Stakeholder Council, shall report to the Senate Finance Committee and the House Health and Government Operations Committee, in accordance with § 2–1257 of the State Government Article, on:
(1) The legality, obstacles, and benefits of setting upper payment limits on all purchases and payor reimbursements of prescription drug products in the State; and
(2) Recommendations regarding whether the General Assembly should pass legislation to expand the authority of the Board to set upper payment limits to all purchases and payor reimbursements of prescription drug products in the State.
Disclaimer: These codes may not be the most recent version. Maryland may have more current or accurate information. We make no warranties or guarantees about the accuracy, completeness, or adequacy of the information contained on this site or the information linked to on the state site. Please check official sources.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.
